Effects of combined treatment with cognitive enhancer memantine and antidepressant fluoxetine on CYP2D2 metabolic activity in rats
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14740%2F11%3A00055489" target="_blank" >RIV/00216224:14740/11:00055489 - isvavai.cz</a>
Výsledek na webu
<a href="http://www.ncbi.nlm.nih.gov/pubmed/22167136" target="_blank" >http://www.ncbi.nlm.nih.gov/pubmed/22167136</a>
DOI - Digital Object Identifier
—
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Effects of combined treatment with cognitive enhancer memantine and antidepressant fluoxetine on CYP2D2 metabolic activity in rats
Popis výsledku v původním jazyce
The drug-drug interactions can result in alterations of the therapeutical responses. The present study was designed to investigate possible pharmacokinetic interactions between the cognitive agent memantine and the antidepressant fluoxetine combined often in treatments of cognitive disorders including Alzheimer disease. The attention was focused on changes of the cytochrome P450 2D2 isoenzyme activity in two animal models. METHODS AND DESIGN: The tested drugs were administered alone or in a combinationto rat males and their effects on the 2D2 isoenzyme activity was determined after in vivo administration. The levels of marker dextromethorphan, its 2D2 specific metabolite dextrorphan were analyzed in plasma of rats and using the model of isolated perfused rat liver in the perfusion medium. The dextromethorphan/ dextrorphan (DEM/DEX) metabolic ratios were determined as a sign of inhibitory influences on CYP2D2.
Název v anglickém jazyce
Effects of combined treatment with cognitive enhancer memantine and antidepressant fluoxetine on CYP2D2 metabolic activity in rats
Popis výsledku anglicky
The drug-drug interactions can result in alterations of the therapeutical responses. The present study was designed to investigate possible pharmacokinetic interactions between the cognitive agent memantine and the antidepressant fluoxetine combined often in treatments of cognitive disorders including Alzheimer disease. The attention was focused on changes of the cytochrome P450 2D2 isoenzyme activity in two animal models. METHODS AND DESIGN: The tested drugs were administered alone or in a combinationto rat males and their effects on the 2D2 isoenzyme activity was determined after in vivo administration. The levels of marker dextromethorphan, its 2D2 specific metabolite dextrorphan were analyzed in plasma of rats and using the model of isolated perfused rat liver in the perfusion medium. The dextromethorphan/ dextrorphan (DEM/DEX) metabolic ratios were determined as a sign of inhibitory influences on CYP2D2.
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FR - Farmakologie a lékárnická chemie
OECD FORD obor
—
Návaznosti výsledku
Projekt
<a href="/cs/project/ED1.1.00%2F02.0068" target="_blank" >ED1.1.00/02.0068: CEITEC - central european institute of technology</a><br>
Návaznosti
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>Z - Vyzkumny zamer (s odkazem do CEZ)
Ostatní
Rok uplatnění
2011
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Neuroendocrinology Letters
ISSN
0172-780X
e-ISSN
—
Svazek periodika
32
Číslo periodika v rámci svazku
5
Stát vydavatele periodika
SE - Švédské království
Počet stran výsledku
6
Strana od-do
727-732
Kód UT WoS článku
000300543900026
EID výsledku v databázi Scopus
—